These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27438815)

  • 1. An NMR-Guided Screening Method for Selective Fragment Docking and Synthesis of a Warhead Inhibitor.
    Khattri RB; Morris DL; Davis CM; Bilinovich SM; Caras AJ; Panzner MJ; Debord MA; Leeper TC
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying Ortholog Selective Fragment Molecules for Bacterial Glutaredoxins by NMR and Affinity Enhancement by Modification with an Acrylamide Warhead.
    Khattri RB; Morris DL; Bilinovich SM; Manandhar E; Napper KR; Sweet JW; Modarelli DA; Leeper TC
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31905878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of (19)F-NMR in Fragment-Based Drug Discovery.
    Norton RS; Leung EW; Chandrashekaran IR; MacRaild CA
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding Mode Prediction and Virtual Screening Applications by Covalent Docking.
    Scarpino A; Ferenczy GG; Keserű GM
    Methods Mol Biol; 2021; 2266():73-88. PubMed ID: 33759121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
    Ma R; Wang P; Wu J; Ruan K
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMR in structure-based drug design.
    Carneiro MG; Ab E; Theisgen S; Siegal G
    Essays Biochem; 2017 Nov; 61(5):485-493. PubMed ID: 29118095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Virtual Screening.
    Li Q; Shah S
    Methods Mol Biol; 2017; 1558():111-124. PubMed ID: 28150235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein structure-based drug design: from docking to molecular dynamics.
    Śledź P; Caflisch A
    Curr Opin Struct Biol; 2018 Feb; 48():93-102. PubMed ID: 29149726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post processing of protein-compound docking for fragment-based drug discovery (FBDD): in-silico structure-based drug screening and ligand-binding pose prediction.
    Fukunishi Y
    Curr Top Med Chem; 2010; 10(6):680-94. PubMed ID: 20337587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docking and Virtual Screening in Drug Discovery.
    Kontoyianni M
    Methods Mol Biol; 2017; 1647():255-266. PubMed ID: 28809009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR-Fragment Based Virtual Screening: A Brief Overview.
    Singh M; Tam B; Akabayov B
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29370102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
    Hoffer L; Renaud JP; Horvath D
    J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of Solution NMR in Drug Discovery.
    Shi L; Zhang N
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Confidence Protein-Ligand Complex Modeling by NMR-Guided Docking Enables Early Hit Optimization.
    Proudfoot A; Bussiere DE; Lingel A
    J Am Chem Soc; 2017 Dec; 139(49):17824-17833. PubMed ID: 29190085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Practical Perspective on the Roles of Solution NMR Spectroscopy in Drug Discovery.
    Li Q; Kang C
    Molecules; 2020 Jun; 25(13):. PubMed ID: 32605297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain.
    Unzue A; Xu M; Dong J; Wiedmer L; Spiliotopoulos D; Caflisch A; Nevado C
    J Med Chem; 2016 Feb; 59(4):1350-6. PubMed ID: 26043365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative docking of dual conformations in human fatty acid synthase thioesterase domain reveals potential binding cavity for virtual screening of ligands.
    John A; Vetrivel U; Subramanian K; Deepa PR
    J Biomol Struct Dyn; 2017 May; 35(6):1350-1366. PubMed ID: 27145135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.